$1.550
-0.145 (-9.36%)At close
Technical Sentiment
Overall Consensus
Technical Analysis Consensus
Moving Average Consensus
X T L Biopharmaceuticals Ltd (XTLB) Moving Averages Convergence Divergence (MACD) indicator is -0.14, suggesting XTLB is Strong sell.
X T L Biopharmaceuticals Ltd (XTLB) 20-Day simple moving average is 1.84, while X T L Biopharmaceuticals Ltd (XTLB) share price is $—, making it Sell.
X T L Biopharmaceuticals Ltd (XTLB) 60-Day simple moving average is 2.23, while X T L Biopharmaceuticals Ltd (XTLB) share price is $—, making it Sell.
Technical Analysis for XTLB
AI Technical XTLBAs of 2026-11-07, the technical board for X T L Biopharmaceuticals Ltd (XTLB) reads strong sell: 2 indicators are flashing buy, 9 are indicating sell, and 2 are neutral. Price at $1.55 sits below every tracked moving average (5-day, 10-day, 20-day, 60-day and 200-day).
Momentum readings: RSI stands at 34.628, MACD stands at -0.139 (Sell), Stochastic %K stands at 18.863 (Buy), Stochastic %D stands at 24.206 and CCI stands at -158.287 (Buy).
XTLB trades below the 60-day SMA (2.23) and below the 200-day SMA (2.65). Immediate resistance sits at Classic R1 2.00, then R2 2.25. Support sits at Classic S1 1.52, then S2 1.29.
X T L Biopharmaceuticals Ltd (XTLB) Support & Resistance Level
X T L Biopharmaceuticals Ltd (XTLB) Technical Indicators
2026-11-07
| Name | Value |
|---|---|
| RSI_14 | 34.628 |
| STOCHk_14_3_3 | 18.863 |
| STOCHd_14_3_3 | 24.206 |
| CCI_20 | -158.287 |
| AO_5_34 | -0.295 |
| MOM_10 | -0.470 |
| MACD_12_26_9 | -0.139 |
X T L Biopharmaceuticals Ltd (XTLB) Relative Strength Index (RSI_14) is 34.628, creating a Neutral signal.
X T L Biopharmaceuticals Ltd (XTLB) Stochastic %K is 18.863, creating a Buy signal.
X T L Biopharmaceuticals Ltd (XTLB) Stochastic %D is 24.206, creating a Neutral signal.
X T L Biopharmaceuticals Ltd (XTLB) CCI_20 is -158.287, creating a Buy signal.
X T L Biopharmaceuticals Ltd (XTLB) Awesome Oscillator (AO) is -0.295, creating a Sell signal.
X T L Biopharmaceuticals Ltd (XTLB) Momentum (MOM) is -0.470, creating a Sell signal.
X T L Biopharmaceuticals Ltd (XTLB) Moving Average Convergence Divergence (MACD) is -0.139, creating a Sell signal.
X T L Biopharmaceuticals Ltd (XTLB) Moving Average
2026-11-07
| Period | Simple | Signal |
|---|---|---|
| MA_5 | 1.677 | Sell |
| MA_10 | 1.740 | Sell |
| MA_20 | 1.840 | Sell |
| MA_60 | 2.230 | Sell |
| MA_200 | 2.647 | Sell |
| MA_250 | 2.781 | Sell |
X T L Biopharmaceuticals Ltd (XTLB) 5-Day simple moving average is 1.677, while X T L Biopharmaceuticals Ltd (XTLB) share price is $, making it a Sell.
X T L Biopharmaceuticals Ltd (XTLB) 10-Day simple moving average is 1.740, while X T L Biopharmaceuticals Ltd (XTLB) share price is $, making it a Sell.
X T L Biopharmaceuticals Ltd (XTLB) 20-Day simple moving average is 1.840, while X T L Biopharmaceuticals Ltd (XTLB) share price is $, making it a Sell.
X T L Biopharmaceuticals Ltd (XTLB) 60-Day simple moving average is 2.230, while X T L Biopharmaceuticals Ltd (XTLB) share price is $, making it a Sell.
X T L Biopharmaceuticals Ltd (XTLB) 200-Day simple moving average is 2.647, while X T L Biopharmaceuticals Ltd (XTLB) share price is $, making it a Sell.
X T L Biopharmaceuticals Ltd (XTLB) 250-Day simple moving average is 2.781, while X T L Biopharmaceuticals Ltd (XTLB) share price is $, making it a Sell.
Related articles
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.